ProCE Banner Activity

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Individualizing Therapy for HR-Positive/HER2-Negative MBC

Slideset

Expert-curated downloadable slideset on guideline-concordant treatment for HR-positive/HER2-negative metastatic breast cancer, with a focus on the appropriate use of CDK4/6 inhibitors and individualized therapy based on emerging data.

Released: October 09, 2024

Expiration: October 08, 2025

Share

Faculty

Julia A LaBarbera

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner